BRAIN Biotech AG

Regulatory Filings • Aug 2, 2017

News Details

Corporate | 2 August 2017 10:03

B.R.A.I.N. Biotechnology Research And Information Network AG: Natural Active Ingredients for Cosmetics – Successful conclusion of joint BRAIN AG and BASF SE research project

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Alliance

02.08.2017 / 10:03

The issuer is solely responsible for the content of this announcement.

---

**Natural Active Ingredients for Cosmetics

Successful conclusion of joint BRAIN AG and BASF SE research project**

• Objective of the research collaboration was the identification and development of new active ingredients for cosmetics
• BRAIN contributed its competence in identifying natural active molecules using specific receptor technologies
• BASF provided comprehensive expertise in product development, production processes, and marketing strategy
• First product launched in the market

Zwingenberg, Germany, 2 August 2017

Following several years of exclusive cooperation between BRAIN AG and BASF SE on the basis of a joint research project, BRAIN today announced the successful conclusion of the project. The objective of the two companies’ collaborative research efforts was the identification and development of sensorically active substances for end consumers.

To this end, BRAIN contributed its specific competencies in the field of identifying natural active substances from its proprietary BioArchive and additionally provided its unique expertise in the receptor technologies sector. Receptor technologies developed by BRAIN serve at laboratory level to predict substance effects on human sense organs. Such a laboratory procedure was successfully established during the research partnership with BASF.

BASF transferred the jointly generated research results to the development and marketing of innovative product candidates. These development efforts have since led to one product’s being successfully launched in the market.

Dr Michael Krohn, member of BRAIN’s Board of Management and Head of the BioActives & Performance Biologicals Unit states:

“We are delighted about the successful conclusion of the research partnership with BASF – particularly about the fact that a first product based on our receptor technologies was already launched in the market. At BRAIN, we use these technologies not only for sustainable cosmetics applications, but also for healthier food developments. For instance, this segment focuses on natural sugar substitutes, sweetness enhancers or taste modulators. Our high-tech portfolio permits us to deliver reliable results in any joint R&D endeavour, and we have more than 100 successfully concluded cooperation projects under our belt.”

Sales-wise, BRAIN’s research cooperation activities are reflected in its BioScience segment, which focuses on exclusive R&D collaborative partnerships with industrial companies. The cooperation partners have agreed to keep contract details about the successfully concluded research cooperation project confidential.

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe’s leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this “Toolbox of Nature” are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN’s business model is based on two pillars – BioScience and BioIndustrial. The BioScience comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN’s own products and active product components. www.brain-biotech.de/en .

Investor Relations Contact

B ž R ž A ž I ž N

Biotechnology Research

And Information Network AG

Dr. Martin Langer

Executive Vice President

Corporate Development

Darmstädter Str. 34-36

64673 Zwingenberg, Germany

Tel.: +49-(0)-6251-9331-16

Fax: +49-(0)-6251-9331-11

E-Mail: ir@brain-biotech.de

www.brain-biotech.de

**Media Contact:

**

B ž R ž A ž I ž N

Biotechnology Research

And Information Network AG

Thomas Deichmann

Head of Public Relations

Darmstädter Str. 34-36

64673 Zwingenberg, Germany

Tel.: +49-(0)-6251-9331-72

Fax: +49-(0)-6251-9331-11

E-Mail: td@brain-biotech.de

www.brain-biotech.de

---

02.08.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de

---

Language:	English
Company:	B.R.A.I.N. Biotechnology Research And Information Network AG
	Darmstädter Straße 34-36
	64673 Zwingenberg
	Germany
Phone:	+49 (0) 62 51 / 9331-0
Fax:	+49 (0) 62 51 / 9331-11
E-mail:	ir@brain-biotech.de
Internet:	www.brain-biotech.de
ISIN:	DE0005203947
WKN:	520394
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange

End of News	DGAP News Service